The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...

Preliminary data from the first-in-human study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that CS5001 is well-tolerated and exhibits encouraging ...

The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat ...

Cleavable linkers dominate the ADC market, driven by their versatility and therapeutic efficacy. Regulatory approvals and ongoing clinical trials underscore the growing adoption of cleavable linker ...

4c15507. Additional experimental details; temperature and time-dependent dissolution of the PAAm with the DHEBA cross-linker; measurement of mechanical properties of the PAAm with the cleavable ...